Immuron Limited has released a press release.
Analyst Reports on Immuron IMM-529 C. difficile Program
Filed with ASX ·
6ix hasn’t read this filing yet.
Later from Immuron
- Immuron Receives $1.47M R&D Tax Concession Refund
- Immuron Secures upto $1.7M Equity & Convertible Note Funding
- Immuron Initiates Pre-Clinical Colitis Development Program
- Appendix 4D - Half Yearly Report and Accounts
- Immuron Improves Hadasit Royalty Terms
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron